Skip to content
PeptideAI
Human trialsskin

Argireline

A SNAP-25 mimic applied to the skin to blunt micro-contractions in expression lines — real but modest, and nothing like an injection of botulinum toxin.

Also known as Acetyl Hexapeptide-8, Acetyl Hexapeptide-3, AH-8, Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2, Argireline, Argireline Amplified Peptide

Human trials — Studied in people, typically early phase or small — promising rather than proven.

The foundational study was a small placebo-controlled trial in 10 women using a 10% solution twice daily for 30 days, reporting roughly a 30% reduction in periorbital wrinkle depth by silicone replica. Independent replication is thin, effect sizes elsewhere are smaller, and penetration to the muscle remains the unresolved weak point.

How it works

SNAP-25 is one of three proteins that zipper together to form the SNARE complex that docks and fuses acetylcholine vesicles at the motor endplate — the same protein botulinum toxin type A cleaves. Argireline is an acetylated hexapeptide copy of the SNAP-25 N-terminal segment; it occupies that position in the assembling complex and destabilises it, so vesicle fusion and neurotransmitter release are reduced rather than abolished. The honest caveat is delivery: at 888 Da and strongly hydrophilic, very little of a topical dose reaches the facial mimetic muscles, so the observed line-softening is likely a mix of a small neuromuscular effect and straightforward hydration and surface smoothing. Manufacturer work also claims effects on stratum corneum water content that are independent of the SNARE mechanism.

Targets: SNAP-25, SNARE complex assembly, Acetylcholine vesicle exocytosis

Dosing

ProtocolDoseFrequencyRoute
Standard anti-wrinkle serumMorning and night on clean skin, before heavier occlusive layers.—twice dailytopical
  • · The published clinical work used a 10% Argireline solution, which corresponds to roughly 0.5% actual peptide because commercial Argireline is supplied as a ~5% aqueous solution. If you are working from raw powder, 0.3-0.5% w/w is the sensible target. Products advertising '10% Argireline' are quoting the diluted trade solution, not the peptide.

Cycling

Used continuously. The effect is not cumulative in the way toxin is; stop applying and lines return over a few weeks.

Work out your exact syringe units →

Pharmacology

Half-life
Not established. It is degraded by skin peptidases over hours; no meaningful systemic exposure from topical use.
Onset
Small changes in expression-line depth appear after about 4 weeks of twice-daily use; peak effect around 8-12 weeks.
Routes
topical
Molecule
Synthetic acetylated hexapeptide amide
Sequence length
6 amino acids
Molecular weight
888.99 Da

Handling

Diluent
Distilled or deionised water
Typical mix
20 or 40 mL
Vial sizes
50, 100, 200 mg
Lyophilised
Cool and dry, sealed; freezer for anything beyond a few months.
Reconstituted
Refrigerated and preserved; unpreserved aqueous solutions should be treated as 2-4 week products.

Mixing

Highly water soluble. 200 mg into 40 mL of base gives 0.5% w/v — a realistic working concentration.

Side effects

  • uncommonMild dryness or tightness— More often from the vehicle than the peptide.
  • uncommonIrritation or stinging at high concentrations— Reported mostly around and above 10% of the trade solution.

Do not use if

  • Broken or actively inflamed skin — the peptide is not the problem, but the vehicle usually is.

Combining it

  • synergysnap-8 — Commonly co-formulated; SNAP-8 hits the same complex with higher affinity.
  • synergyleuphasyl — Presynaptic enkephalin mimicry plus SNARE interference; the classic Lipotec pairing.
  • redundantbotulinum-toxin-type-a — If you are already getting toxin injections, topical SNARE peptides add essentially nothing in the treated area.

What to monitor

  • · Standardised photographs at rest and in full expression; the only honest way to judge this one.

Legal status

Cosmetic ingredient (INCI Acetyl Hexapeptide-8) approved for use worldwide; no drug status anywhere.

References

  • Blanes-Mira et al. 2002, a synthetic hexapeptide with antiwrinkle activity (Int J Cosmet Sci) (trial)
  • Lubrizol/Lipotec Argireline technical dossier (other)

Mechanism in depth

The biochemistry is genuinely elegant and the delivery is genuinely hopeless, and holding both of those at once is the only honest way to describe this compound. SNARE-mediated vesicle fusion requires SNAP-25, syntaxin-1A and VAMP/synaptobrevin to zipper into a four-helix coiled-coil that drags the vesicle membrane against the plasma membrane hard enough to fuse them. SNAP-25 contributes two of those four helices, one from its N-terminal region and one from its C-terminal region. Blanes-Mira's group showed that a hexapeptide copy of the SNAP-25 N-terminal segment competes for its own slot in the assembling complex and destabilises it, reducing calcium-dependent exocytosis in a cell-free assay. That is real, reproducible biochemistry. Now the problem. The concentrations at which that competition works in vitro are micromolar in a system with no membrane barrier. Topically, 0.01% of an applied dose reaches viable epidermis and nothing detectable reaches dermis, let alone the frontalis or orbicularis oculi sitting beneath the subcutis. So whatever line-softening people observe is almost certainly not neuromuscular. The plausible alternative mechanisms are dull but real: a hygroscopic, highly charged hexapeptide sitting in the stratum corneum increases corneocyte water content, and hydrated stratum corneum swells and visually flattens fine surface lines. That is the same mechanism as a good humectant. It reverses within hours of stopping, which is exactly what people report. Lipotec's own dossier claims stratum corneum water content effects independent of SNARE, which is quietly consistent with this reading.

What usually goes wrong

The concentration confusion is the single biggest practical trap. Commercial Argireline is supplied as roughly a 5% aqueous solution, so a product boasting '10% Argireline' contains about 0.5% actual peptide, and a DIY maker who dissolves powder to 10% has made something twenty times stronger than the trial formulation without realising it. That is where the irritation reports come from. The second failure is expectation calibration: people buy this expecting something on the Botox spectrum and get something on the hyaluronic acid spectrum. Static lines — the creases that are there when your face is relaxed — will not move, because they are collagen loss, not muscle activity. Third, the effect washes out fast. Stop applying and the lines are back in days to a couple of weeks, which is not how a genuine neuromuscular effect behaves and is exactly how a hydration effect behaves. Fourth, judging it in a mirror. Take standardised photographs at rest and in full expression, same lighting, same distance, or you are just measuring your mood.

Titration ladder

  1. —0-2 — 0.1% w/w actual peptide, twice daily. From raw powder this is 100 mg into 100 mL of base.
  2. —2+ — 0.3-0.5% w/w actual peptide, twice daily. This bracket corresponds to the 10% trade solution used in the original trial. There is no reason to go higher — irritation reports cluster above this and the penetration ceiling is not concentration-limited.

Pharmacokinetics

Bioavailability
0.23%
Crosses blood-brain barrier
no
Metabolism
Degraded by skin peptidases to constituent amino acids. The N-terminal acetylation blocks aminopeptidase attack and the C-terminal amidation blocks carboxypeptidase attack, which is why it is stable in formulation for years — those two modifications are the whole reason it is usable as a cosmetic ingredient.
Elimination
No meaningful systemic exposure from topical use. The Cosmetic Ingredient Review panel's 2025 safety assessment concluded it is safe as used in cosmetics, largely on the strength of the negligible penetration.

Receptor targets

  • SNAP-25 N-terminal binding site within the assembling SNARE complex — Not published as a Kd. Competition demonstrated in cell-free exocytosis assays at micromolar concentrations.

    Destabilises SNARE zippering, reducing but not abolishing calcium-dependent acetylcholine vesicle fusion. Reversible and competitive, unlike botulinum toxin's catalytic cleavage.

  • Stratum corneum water binding — Not a receptor interaction

    The most likely actual mechanism behind the observed cosmetic effect. Two glutamates and two arginines make this a strongly hygroscopic molecule.

Trials

  • Blanes-Mira placebo-controlled evaluation of Argireline in an oil-in-water emulsion Small controlled human evaluation · 4 weeks · 2002

    Approximately 30% reduction in wrinkle depth by silicone replica after 30 days of twice-daily 10% Argireline solution. This is the study every marketing claim traces back to. It is small, it is by the peptide's developers, and it has never been independently replicated at that effect size.

  • Zhu et al. clinical evaluation of a serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate and gluconolactone (Int J Cosmet Sci) Ex vivo plus two clinical studies · n=50 · 12 weeks · 2026

    Static-wrinkle clinical scoring improved 35-69% across wrinkle types at 12 weeks (p < 0.001); a second arm of 42 subjects showed 10-13% improvement in dynamic wrinkle scores. Ex vivo work showed increased elastic and collagen fibres. Multi-ingredient, so it cannot isolate the hexapeptide.

  • An et al. cross-linked hyaluronic acid microneedle patch with acetyl hexapeptide-8 and EGF on Korean skin (Ann Dermatol) Clinical efficacy study · 2019

    Anti-wrinkle efficacy of a microneedle delivery format. Relevant because microneedle delivery is the only route that plausibly bypasses the penetration problem described above.

What to expect, and when

Day 1-3: a subtle immediate smoothing that is film-forming and hydration, not peptide. Week 4: the point at which the original trial started to register replica-measured change. Week 8-12: peak of whatever effect you are going to get. There is no further accumulation past twelve weeks. Discontinuation: reversal within roughly two weeks, sometimes faster.

Stacking and comparisons

Argireline is chemically inert toward almost everything, which is why it appears in hundreds of formulas — it is stable across cosmetic pH, it does not oxidise, and it does not fight with acids, retinoids or vitamin C. The standard neuromuscular stack is Argireline plus SNAP-8 plus Leuphasyl plus a postsynaptic blocker like Syn-Ake or Vialox, sold as hitting four points on one pathway. Be clear-eyed about that: stacking four peptides that each fail to reach the muscle does not produce one that does. If the effect you are getting is stratum corneum hydration, you would get more of it from a well-built humectant system at a tenth of the price. The genuinely useful pairing is Argireline with a structural peptide — Matrixyl, Matrixyl 3000 or GHK-Cu — because those address a different problem (collagen loss) through a different tissue (dermis) on a different timescale. And if you are already having botulinum toxin in an area, topical SNARE peptides in that area are simply redundant.

Against botulinum toxin this is not a comparison, it is a category error, and the site should say so plainly. Toxin is injected directly into the muscle, is catalytic rather than competitive, destroys its substrate at picomolar concentrations and produces functional denervation for three to four months with phase-3 randomised evidence behind it. Argireline reaches 0.01% of applied dose into viable epidermis. Against SNAP-8, SNAP-8 binds the SNARE site more tightly in vitro but is 1075 Da versus 889 Da, so it penetrates even worse — the affinity gain is cancelled by the delivery loss, and neither has been measured at the muscle. Against Matrixyl, Matrixyl has the better human trial and addresses a structural problem that actually responds to topicals. If you can only run one peptide, run the matrikine.

Rough cost

$8–$60/month. Raw acetyl hexapeptide-8 powder runs roughly $15-40 per gram; one gram at 0.5% makes 200 mL of serum. Finished serums range from about $12 for basic drugstore formulas to $60 a month for prestige ones. Market observation, not a sourced pricing study.

Genuinely uncertain

  • The original Blanes-Mira study's participant count is usually quoted as 10 women, but I could not confirm that number from the abstract in this session. The 30% figure and the 30-day duration are confirmed.
  • No study has ever measured Argireline concentration at a facial mimetic muscle in a living human. The neuromuscular mechanism is inferred entirely from cell-free assays.
  • The relative contribution of hydration versus SNARE interference to the observed clinical effect has never been separated experimentally.
  • Whether the two extra residues in SNAP-8 translate into any in vivo advantage is unknown, and both compounds are usually sold together, which makes attribution impossible.
  • The molecular weight of 888.99 Da in the Core record is for the free peptide; commercial material is usually supplied as an acetate salt in aqueous solution, so vendor assay figures differ.

Papers